Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 2;9:18069. doi: 10.1038/s41598-019-54438-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Overall survival (OS) of patients with metastatic melanoma treated with AdCD40L gene therapy assessed by fold change (F) F ADC, F D and F SUV_max of the injected metastases. The analyses were conducted excluding the patients who did not undergo all examinations (n = 13). The Kaplan-Meier method was used followed by log-rank tests. (a) The median OS of patients with F D ≥ 1 (black lines) compared with those with F D < 1 (grey lines) observed in Scan 1 at week 5 (p = 0.075).(b) The median OS of the patients with F D ≥ 1 (black line) compared with the median OS of the patients with F D < 1 (grey line) in Scan 2 at week 9 (p = 0.001).(c) Comparison of the median OS in patients with F ADC ≥ 1 (black lines) and those with F ADC < 1 (grey lines) in Scan 1 at week 5 (p = 0.15).(d) Comparison of the median OS of the patients with F ADC ≥ 1 (black line) to the median OS of the patients with F ADC < 1 (grey line) in Scan 2 at week 9 (p = 0.014). (* indicates p < 0.05).